This happens via the positron emission of a gallium 68 dotatate injection, an active agent for positron emission tomography (PET) imaging. NETSPOT is a radioactive probe that helps track down and pinpoint NETs. Designated ACR Lung Cancer Screening Center at all four locations: Northwest, Central Valley, Southwest and Henderson. The amount of radiation used is much lower than standard doses of a CT scan and contrast dye should not be used. LDCT is used to find nodules in the lungs and takes many pictures of the inside of your body from different angles using x-rays. Comprehensive Cancer Centers of Nevada offers screening with low-dose computed tomography (CT) for people at high risk for lung cancer, the only recommended screening test for the disease. It is commonly used in detecting, diagnosing and staging cancer.Įarly detection is a proven, successful strategy for fighting many forms of cancer. The following diagnostic imaging services are available:Īxumin PET Scans are offered at Comprehensive Cancer Centers to achieve early detection of recurrent prostate cancer after surgery or radiation.Ĭomputed Tomography (CT) is an imaging tool that uses special x-ray equipment to reveal the body’s detailed anatomic structure with great clarity. Comprehensive Cancer Centers’ treatment centers are equipped with Nevada imaging services, making access to tests and scans convenient for you, and ensuring your physicians have timely access to the results. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.Diagnostic imaging and medical scans are vital in accurately diagnosing and cancer staging, as well as tracking the progress of treatment. The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. Netspot is marketed by Advanced Accelerator Applications USA, Inc. No serious adverse reactions have been identified. Netspot contributes to overall long-term cumulative radiation exposure, and patients should drink and urinate as often as possible during the first hours following administration to help reduce this risk. The results of all three studies confirmed the usefulness of Ga-68 dotatate images in finding the location of the neuroendocrine tumors. The first compared Ga-68 dotatate images of neuroendocrine tumors to images obtained with an approved drug, and then confirmed with computed tomography (CT) and/or magnetic resonance imaging (MRI) the second evaluated Ga-68 dotatate images using histopathology or clinical follow up as reference standards and the third evaluated patients with neuroendocrine tumor recurrence using Ga-68 dotatate images. Three studies established the safety and effectiveness of Netspot. The uptake of Ga-68 dotatate may need to be confirmed by histopathology or other assessments. This uptake can also be seen in a variety of other tumor types or other pathologic conditions, or might occur as a normal variant. The uptake of Ga-68 dotatate reflects the level of somatostatin receptor density in neuroendocrine tumors. Netspot is supplied as a sterile, single-dose kit for preparation of Ga-68 dotatate injection for intravenous use. This information is important for planning the appropriate course of therapy.” “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. “Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,” said Libero Marzella, MD, PhD, Director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. Ga-68 dotatate, a positron-emitting analog of somatostatin, works by binding to such receptors. Neuroendocrine tumors have receptors for somatostatin, a hormone that regulates the endocrine system. These cells are found throughout the body in organs, such as the stomach, intestines, pancreas, lungs, and others. Neuroendocrine tumors are rare tumors, which can be benign or malignant, that develop in the hormone-producing cells of the body’s neuroendocrine system. This radioactive probe will help locate tumors in adult and pediatric patients with somatostatin receptor–positive neuroendocrine tumors. Food and Drug Administration (FDA) today approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging.
0 kommentar(er)
